31 research outputs found

    Impairment of IFN-Gamma Response to Synthetic Peptides of Mycobacterium tuberculosis in a 7-Day Whole Blood Assay

    Get PDF
    Studies on Mycobacterium tuberculosis (MTB) antigens are of interest in order to improve vaccine efficacy and to define biomarkers for diagnosis and treatment monitoring. The methodologies used for these investigations differ greatly between laboratories and discordant results are common. The IFN-gamma response to two well characterized MTB antigens ESAT-6 and CFP-10, in the form of recombinant proteins and synthetic peptides, was evaluated in HIV-1 uninfected persons in both long-term (7 day) and 24 hour, commercially available QuantiFERON TB Gold in Tube (QFT-GIT), whole blood assays. Our findings showed differences in the IFN-gamma response between 24 hour and 7 day cultures, with recombinant proteins inducing a significantly higher response than the peptide pools in 7 day whole blood assays. The activity of peptides and recombinant proteins did not differ in 24 hour whole blood or peripheral blood mononuclear cell (PBMC) based assays, nor in the ELISpot assay. Further analysis by SELDI-TOF mass spectrometry showed that the peptides are degraded over the course of 7 days of incubation in whole blood whilst the recombinant proteins remain intact. This study therefore demonstrates that screening antigenic candidates as synthetic peptides in long-term whole blood assays may underestimate immunogenicity

    Studies on in vitro human T cell reactivity to antigens of mycobacterium tuberculosis

    Get PDF
    Studies on Mycobacterium tuberculosis (MTB) antigens are important to improve immunodiagnostics and vaccine efficacy. A novel genome based strategy for antigen discovery is to relate what is highly expressed by bacilli in vivo or in vitro, to what is recognized by human T cells as antigens. As hypoxia is a relevant stimulus that MTB encounters in vivo, whole genome based transcriptional profiles of M. tuberculosis subject to prolonged hypoxia (described as the Enduring hypoxic response (EHR) were analyzed, to guide the discovery of novel potential anitgens, by a combined bioinformatic and empirical approach and to determine evidence of infection stage specific recognition

    SELDI-TOF mass spectrometry analysis of whole blood supernatant stimulated with ESAT-6 and CFP-10 peptide pools.

    No full text
    <p>(A) ESAT-6 peptide pool stimulated whole blood at Day 0 with expected masses from 1419 Da to 1738 Da. (B) ESAT-6 peptide pool stimulated whole blood harvested after 7 days of incubation. (C) CFP-10 peptide pool stimulated whole blood at Day 0 with expected masses from 1415 Da to 1804 Da. (D) CFP-10 peptide pool stimulated whole blood harvested after 7 days of incubation.</p

    IFN-gamma response of PBMC to peptide pools and recombinant proteins in the overnight ELISpot assay (n = 29).

    No full text
    <p>“PP” indicates the peptide pools and “r” indicates recombinant proteins of ESAT-6 and CFP-10. No significant difference was found between the peptide pool and recombinant protein for either ESAT-6 or CFP-10 (Wilcoxon matched pairs test). Lines indicate median response.</p

    QFT-IT results, representing the Antigen-Nil IU/ml INF-gamma values (n = 29, Panel A).

    No full text
    <p>The solid line represents the median. <b>IFN-gamma response to peptide pools (covering ESAT-6, CFP-10, and Rv2654) and recombinant ESAT-6 and CFP-10 in the 7 day WBA (n = 29, Panel B).</b> “PP” indicates peptide pool and “r” indicates the recombinant proteins. Recombinant proteins induced significantly higher responses than the peptide pools (p<0.0001 for both ESAT-6 and CFP-10). IFN-gamma concentrations are shown as pg/ml. Lines indicate median response.</p

    Recombinant ESAT-6 protein profiles on SELDI-TOF mass spectrometry.

    No full text
    <p>(A) Recombinant rESAT-6 protein. (B) Recombinant ESAT-6 stimulated whole blood at Day 0 showing a peak at the predicted molecular weight of 11.7 kDa. (C) Recombinant ESAT-6 stimulated whole blood after 7 days of incubation showing that rESAT-6 cannot be detected, while a new peak appears at 10.8 kDa.</p
    corecore